Long-term administration of fatty acid amide hydrolase inhibitor (URB597) to rats with spontaneous hypertension disturbs liver redox balance and phospholipid metabolism

Adv Med Sci. 2019 Mar;64(1):15-23. doi: 10.1016/j.advms.2018.06.002. Epub 2018 Sep 19.

Abstract

Purpose: The effect of chronic administration of [3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate (URB597), inhibitor of fatty acid amide hydrolase (FAAH) that hydrolyzes anandamide, on cross-talk between endocannabinoid system, oxidative status and pro-inflammatory factors in the liver of spontaneously hypertensive rats (SHRs) was investigated.

Materials/methods: Experiments were conducted using SHRs and normotensive control Wistar-Kyoto rats treated by intraperitoneal injection with URB597 for 14 days. The biochemical parameters were assayed in the rat's livers.

Results: In the liver of SHRs an increase in endocannabinoids level, the activity of enzymes degrading them and expression of the cannabinoid receptor type 2 (CB2) receptor as well as a decrease in the expression of the CB1 and vanilloid 1 receptor (TRPV1) were shown. These changes were related to inflammatory conditions as well as oxidative stress resulting from increased reactive oxygen species (ROS) generation due to enhanced activity of enzymes generating ROS accompanied by decrease in the effectiveness of transcription activity of nuclear factor erythroid 2 and the activity of antioxidant enzymes, as well as level of glutathione and vitamins. Chronic administration of URB597 to SHRs caused a decrease in FAAH activity and an increase in anandamide and N-arachidonoyl-dopamine level as well as a decrease in CB2 and an increase in TRPV1 receptor expression. The levels/activities of pro- and antioxidant and inflammatory factors tended to normalize, but phospholipid peroxidation and DNA modifications were increased.

Conclusion: In conclusion, long-term chronic administration of URB597 to SHRs by altering interactions between endocannabinoid and redox systems enhances some liver metabolic disturbances observed in hypertension.

Keywords: Endocannabinoid system; Hypertension; Inflammation; Liver; Oxidative stress.

MeSH terms

  • Amidohydrolases / antagonists & inhibitors*
  • Amidohydrolases / metabolism
  • Animals
  • Benzamides / administration & dosage*
  • Benzamides / pharmacology
  • Benzamides / therapeutic use*
  • Carbamates / administration & dosage*
  • Carbamates / pharmacology
  • Carbamates / therapeutic use*
  • Endocannabinoids / metabolism
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use*
  • Fatty Acids / metabolism
  • Hypertension / drug therapy*
  • Hypertension / metabolism*
  • Lipid Metabolism* / drug effects
  • Male
  • NF-kappa B / metabolism
  • Oxidation-Reduction / drug effects
  • Phospholipids / metabolism*
  • Rats
  • Reactive Oxygen Species / metabolism
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Benzamides
  • Carbamates
  • Endocannabinoids
  • Enzyme Inhibitors
  • Fatty Acids
  • NF-kappa B
  • Phospholipids
  • Reactive Oxygen Species
  • Tumor Necrosis Factor-alpha
  • cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester
  • Amidohydrolases
  • fatty-acid amide hydrolase